Stiefel Laboratories Announces Duac Topical Gel Now Available In Italy

Published: Sep 26, 2006

CORAL GABLES, Fla., Sept. 25 /PRNewswire/ -- Stiefel Laboratories, Inc., the world's largest independent pharmaceutical company specializing in dermatology, announced Duac(R) Topical Gel (clindamycin, 1% - benzoyl peroxide, 5%) is now available in Italy. Duac Topical Gel is a dual-action, topical acne medication containing clindamycin and benzoyl peroxide indicated for the treatment of inflammatory acne vulgaris.

Duac Topical Gel has been the most successful product introduced in the history of Stiefel Laboratories. Duac has been available in the U.S. since 2002 where it has been the fastest growing topical prescription product for the treatment of acne on the market. Duac is now enjoying very successful introductions in the European Union: Most notably in Germany and Spain where Duac Topical Gel is currently No.1 in the market, and in the United Kingdom where it holds the No.2 position, among prescription medications for the treatment of acne. Duac Topical Gel is currently available in more than 20 countries around the world.

According to Pascal Waucquez, General Manager at Stiefel Laboratories' Italian subsidiary, Duac Topical Gel is generating considerable interest among Italian dermatologists. "We are so pleased to be able to answer the needs of dermatologists for a new, efficacious acne treatment in Italy and look forward to achieving similar launch results in Italy as has occurred in Germany, Spain and the UK," said Mr. Waucquez.

"The launch of Duac Topical Gel in Italy demonstrates the commitment of Stiefel Laboratories to continually expand product offerings for dermatological conditions," said Gabriel McGlynn, Area Vice President, Stiefel Laboratories, Inc. Europe, Middle East, Africa. "Additionally, Stiefel Laboratories continues to provide technological advances in the treatment of skin diseases," he continued.

About Duac Topical Gel

Duac Topical Gel was introduced in 2002 for the topical treatment of inflammatory acne vulgaris. It is a combination therapy containing the active ingredients clindamycin and benzoyl peroxide. Duac Topical Gel is the only dual therapy prescription medication approved for once daily application. The product does not require refrigeration by the patient.

Side effects of Duac Topical Gel may include redness, peeling, burning and dryness. Clindamycin, an ingredient of Duac Topical Gel, may cause diarrhea. If you are using DUAC and experience severe diarrhea, stop using Duac Topical Gel and consult your physician immediately. You should not use Duac Topical Gel if you are allergic to clindamycin, the antibiotic lincomycin, benzoyl peroxide, any of its components or if you have a history of colitis.

About Stiefel Laboratories, Inc.

Founded in 1847, Stiefel Laboratories is the world's largest independent pharmaceutical company specializing in dermatology. The company manufactures and markets a variety of prescription and non-prescription dermatological products. Its wholly-owned global network is comprised of more than 30 subsidiaries, including manufacturing plants in six countries, Research and Development facilities on three continents and products marketed in 100 countries around the world.

Stiefel Laboratories supplements its R&D efforts by aggressively seeking acquisitions of dermatological product lines and companies around the world. To learn more about Stiefel Laboratories, Inc., visit www.stiefel.com.

Full prescribing information is available at: http://www.stiefel.com/products/inserts/DUAC%20PI%20Rev%200104.pdf

Stiefel Laboratories, Inc.

CONTACT: Denise Ulrich of Stiefel Laboratories, Inc., +1-678-765-4104, orcellular, +1-770-656-9338, or dulrich@stiefel.com

Back to news